Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Tempus said the FDA cleared its ECG-MR AI product, which analyzes 12-lead ECGs to detect signs associated with undiagnosed moderate or severe mitral regurgitation. The company said ECG-MR is its fourth FDA-cleared ECG-AI product.
Tempus AI, Inc. (NASDAQ:TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-MR, an AI product that analyzes standard 12-lead resting electrocardiograms (ECGs) to detect signs associated with undiagnosed moderate or severe mitral regu…